Will Grail submit a new FDA filing or announce a clinical trial partnership by October 16, 2026?
Posted 2026-10-02 — 14 days before the deadline, stated before the outcome.
Grail is a biotechnology company focused on developing multi-cancer early detection tests. The U.S. Food and Drug Administration (FDA) regulates the approval of such diagnostic devices, requiring specific regulatory submissions for market authorization.
The claim
Grail will not submit a new FDA regulatory filing or announce a new clinical trial partnership by October 16, 2026.
Reasoning trace
- The current signals provided are entirely unrelated to Grail (focusing on Amazon, Dell, Marvell, Intel, NVIDIA, and Synopsys).
- Grail recently presented PATHFINDER 2 results at ASCO 2026, which is a major data release that typically precedes a period of analysis rather than immediate subsequent filings.
- The surge in coverage (z=4.9) may be algorithmic noise or retrospective analysis of the ASCO data rather than news of a new pending event.
Evidence so far
0 confirming · 0 denying signals · 1 verified · 2 broken assumptions. The evidence itself is part of the full dossier.
Probability history
Updated 5 times since mint (last on 2026-10-09) — 78% at mint → 82% today.
What to watch
- leading indicator Grail announces a new clinical trial partnership or collaboration agreement in a public press release
- milestone Grail or a partner submits a ClinicalTrials.gov registration for a new multi-center or collaborative trial
- leading indicator A named academic or hospital partner publicly confirms a data-sharing or research agreement with Grail
The full dossier behind this prediction — the evidence trail, the risk analysis, the monetization scenarios — is available on request: [email protected].
Probabilities are calibrated against the system's own resolved history; after the deadline the outcome is resolved and audited — including the calls we get wrong. Nothing on this page is investment advice.